Table 3:

Separate analyses to examine the predictive significance of baseline demographic and clinical variables for serial FVC% 3 to 12 months^*

	MMF Arm		CYC Arm
Baseline variable	Point estimate (95% CI)	p-value	Point estimate (95% CI)	p-value
Age in year	−0.05 (−0.18 to 0.08)	0.462	0.04 (−0.06 to 0.15)	0.411
Female Sex	0.04 (−0.53 to 0.69)	0.891	1.17 (−0.09 to 2.26)	0.058
African American race	−0.68 (−1.26 to −0.13)	0.032†	−2.4 (−3.04 to −1.9)	<0.001†
Diffuse disease type	1.15 (0.43 to 2.06)	0.005†	−1.97 (−3.34 to −0.77)	0.008†
Disease duration	0.04 (−0.06 to 0.15)	0.314	0.12 (0.01 to 0.25)	0.042†
mRSS	0.07 (0.04 to 0.11)	0.002†	−0.04 (−0.14 to 0.06)	0.392
Anti-Topoisomerase	−0.14 (−1.12 to 0.81)	0.729	−0.35 (−2.23 to 1.62)	0.654
Anti-RNA polymerase	0.83 (−0.61 to 2.06)	0.175	1.08 (−2.08 to 4.17)	0.425
Extensive disease on HRCT #	−2.45 (−2.85 to −2.11)	<0.001†	0.09 (−2.18 to 2.36)	0.79

^*Each row represents a separate model that included one baseline clinical variable, baseline FVC% and time as independent variables

^†Baseline demographic and clinical variables showing predictive significance in separate models that were included in the subsequent extended multivariable model (Tables 4 and 5).

^#QILD >20% on high resolution chest CT (HRCT)